摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-phenethyl-4H-furo[3,2-b]pyrrole-5-carboxylic acid | 1000402-10-7

中文名称
——
中文别名
——
英文名称
3-phenethyl-4H-furo[3,2-b]pyrrole-5-carboxylic acid
英文别名
3-(2-phenylethyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid
3-phenethyl-4H-furo[3,2-b]pyrrole-5-carboxylic acid化学式
CAS
1000402-10-7
化学式
C15H13NO3
mdl
——
分子量
255.273
InChiKey
CUCMYHOPTSUPIM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    66.2
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
    申请人:Heffernan L. R. Michele
    公开号:US20080004327A1
    公开(公告)日:2008-01-03
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR 1 and N. X and Y are members independently selected from O, S, CR 2 , N and NH. R 1 , R 2 and R 4 are members independently selected from H and F, provided that at least one member selected from R 1 , R 2 and R 4 is F. R 6 is a member selected from O − X + and OH, wherein X + is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    这项发明提供了D-氨基酸化酶的新型抑制剂,以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病,如神经精神病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构:其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员,前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员,其中X+是正离子,从无机正离子和有机正离子中选择的成员。
  • Fused heterocyclic inhibitors of D-amino acid oxidase
    申请人:Heffernan L. R. Michele
    公开号:US20080058395A1
    公开(公告)日:2008-03-06
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .
    本发明提供了D-氨基酸化酶的新型抑制剂,以及包括该发明化合物的制药组合物。同时,还提供了治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构:其中Q是从O、S、CR1和N中选择的成员,X和Y是独立选择自CR2、O、S、N和NR3的成员。
  • FUSED HETEROCYCLES
    申请人:Dorsey James M.
    公开号:US20100029741A1
    公开(公告)日:2010-02-04
    This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula: in which R 1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 3 is a member selected from the group consisting of H, C 1 -C 6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 4 is a member selected from OH and O − X + , in which X + is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. The index n is an integer from 1 to 4.
    本发明提供了通过向受试者给予具有以下公式的融合杂环的治疗有效量来提高认知功能的方法:其中R1是从H、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R2是从H、取代或未取代的基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R3是从H、C1-C6取代或未取代的烷基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R4是从OH和O-X+中选择的成员,其中X+是有机阳离子和无机阳离子中选择的成员中的正离子。取代或未取代的芳基烷基和取代或未取代的杂芳基烷基基团具有以下公式:其中Ar是从取代或未取代的芳基和取代或未取代的杂芳中选择的成员。指数n是1到4的整数。
  • US7579370B2
    申请人:——
    公开号:US7579370B2
    公开(公告)日:2009-08-25
  • US7884124B2
    申请人:——
    公开号:US7884124B2
    公开(公告)日:2011-02-08
查看更多

同类化合物

(E,Z)-他莫昔芬N-β-D-葡糖醛酸 (E/Z)-他莫昔芬-d5 (4S,5R)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S,5R,5''R)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (4R,5S)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R,4''R,5S,5''S)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (1R,2R)-2-(二苯基膦基)-1,2-二苯基乙胺 鼓槌石斛素 黄子囊素 高黄绿酸 顺式白藜芦醇三甲醚 顺式白藜芦醇 顺式己烯雌酚 顺式-白藜芦醇3-O-beta-D-葡糖苷酸 顺式-桑皮苷A 顺式-曲札芪苷 顺式-二苯乙烯 顺式-beta-羟基他莫昔芬 顺式-a-羟基他莫昔芬 顺式-3,4',5-三甲氧基-3'-羟基二苯乙烯 顺式-1-(3-甲基-2-萘基)-2-(2-萘基)乙烯 顺式-1,2-双(三甲基硅氧基)-1,2-双(4-溴苯基)环丙烷 顺式-1,2-二苯基环丁烷 顺-均二苯乙烯硼酸二乙醇胺酯 顺-4-硝基二苯乙烯 顺-1-异丙基-2,3-二苯基氮丙啶 非洲李(PRUNUSAFRICANA)树皮提取物 阿非昔芬 阿里可拉唑 阿那曲唑二聚体 阿托伐他汀环氧四氢呋喃 阿托伐他汀环氧乙烷杂质 阿托伐他汀环(氟苯基)钠盐杂质 阿托伐他汀环(氟苯基)烯丙基酯 阿托伐他汀杂质D 阿托伐他汀杂质94 阿托伐他汀杂质7 阿托伐他汀杂质5 阿托伐他汀内酰胺钠盐杂质 阿托伐他汀中间体M4 阿奈库碘铵 锌(II)(苯甲醛)(四苯基卟啉) 银松素 铜酸盐(5-),[m-[2-[2-[1-[4-[2-[4-[[4-[[4-[2-[4-[4-[2-[2-(羧基-kO)苯基]二氮烯基-kN1]-4,5-二氢-3-甲基-5-(羰基-kO)-1H-吡唑-1-基]-2-硫代苯基]乙烯基]-3-硫代苯基]氨基]-6-(苯基氨基)-1,3,5-三嗪-2-基]氨基]-2-硫代苯基]乙烯基]-3-硫代 铒(III) 离子载体 I 铀,二(二苯基甲酮)四碘- 钾钠2,2'-[(E)-1,2-乙烯二基]二[5-({4-苯胺基-6-[(2-羟基乙基)氨基]-1,3,5-三嗪-2-基}氨基)苯磺酸酯](1:1:1) 钠{4-[氧代(苯基)乙酰基]苯基}甲烷磺酸酯 钠;[2-甲氧基-5-[2-(3,4,5-三甲氧基苯基)乙基]苯基]硫酸盐 钠4-氨基二苯乙烯-2-磺酸酯